CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study

The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus

(2017) Chenglong Fang et al.   MEDICINE

CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice

(2015) Xiaobei Wu et al.   ACTA HISTOCHEMICA

The role of cytokines in the pathogenesis of cutaneous lupus erythematosus

(2015) E.S. Robinson et al.   CYTOKINE

Advances in the assessment of lupus disease activity and damage

(2014) Vijay Rao et al.   CURRENT OPINION IN RHEUMATOLOGY

Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status

(2014) Violaine K. Harris et al.   Molecular Diagnosis & Therapy

CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

(2014) Stinne Ravn Greisen et al.   ARTHRITIS RESEARCH & THERAPY

Understanding How Cutaneous Lupus Erythematosus Progresses to Systemic Lupus Erythematosus

(2014) Benjamin F. Chong   JAMA Dermatology

Systemic Symptoms in the Progression of Cutaneous to Systemic Lupus Erythematosus

(2014) Isabela T. Wieczorek et al.   JAMA Dermatology

CXCL13 is elevated in Sjögrenˈs syndrome in mice and humans and is implicated in disease pathogenesis

(2013) Jill M. Kramer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Biomarkers for systemic lupus erythematosus

(2012) Joseph M. Ahearn et al.   Translational Research

CXCL13 chemokine in pediatric and adult neuroborreliosis

(2011) N. Wutte et al.   ACTA NEUROLOGICA SCANDINAVICA

Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus

(2011) Rachel Klein et al.   ARCHIVES OF DERMATOLOGY

Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement

(2011) MHM Ezzat et al.   LUPUS

Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus

(2011) S Freutel et al.   LUPUS

Elevation of serum CXCL13 in SLE as well as in sepsis

(2010) L Schiffer et al.   LUPUS

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study

(2009) Jason W. Bauer et al.   ARTHRITIS AND RHEUMATISM

Effects of tobacco smoke on immunity, inflammation and autoimmunity

(2009) Yoav Arnson et al.   JOURNAL OF AUTOIMMUNITY

Serum BLC/CXCL13 Concentrations and Renal Expression of CXCL13/CXCR5 in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

(2009) H.-T. LEE et al.   JOURNAL OF RHEUMATOLOGY

B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE)

(2009) L. Schiffer et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia

(2008) D. Sansonno et al.   CURRENT MEDICINAL CHEMISTRY